require an additional, nonintegrated sample preparation step, whereas some also require separate nucleic acid amplification [7] [8] [9] . The development of new NATs with simplified chemistry and procedures that do not require complex instrumentation is essential if this powerful technology is to be successfully transferred to resource-limited settings. NATs based on visual detection of viral nucleic acid by dipstick are therefore a welcome tool for settings with limited resources [10] . Currently available HIV-1 tests have predominantly been optimized for the viral subtype prevalent in developed countries (subtype B), which because of the relatively low infection rates in these countries, is responsible for only ∼10% of HIV-1 infections worldwide [11] . Such assays may perform suboptimally with samples from HIV-1-infected individuals in developing countries [12, 13] , where a large range of subtypes and recombinant forms are prevalent. There is therefore also a need for providing tests that are specifically designed to optimally detect nucleic acid targets of a broad range of HIV-1 subtypes, particularly the non-B strains.
We now describe a new NAT platform, simple amplificationbased assay (SAMBA), for HIV-1 testing. The core component of the SAMBA HIV-1 test that makes it suitable for POC applications is a proprietary signal amplification technology for rapid visual detection of nucleic acid [14] . In contrast to conventional NATs, the SAMBA test relies on isothermal amplification and has a visual readout. It does not require expensive or complex instrumentation and is therefore intended to be affordable for routine use in resource-poor settings. The Royal London Hospital, and archived plasma specimens from blood donors at the Komfo Anokye Teaching Hospital Blood Bank in Kumasi, Ghana, rendered anonymous and provided blindly, were used to establish the subtype coverage and analytical sensitivity of the SAMBA HIV-1 assay. The archived plasma specimens were also assayed with rapid tests for antibodies to both HIV-1 and HIV-2, and their viral loads were determined as described elsewhere [15] . The research use of these specimens was approved by the Committee on Human Research Publication and Ethics of the University of Science and the Technology School of Medical Sciences in Kumasi.
METHODS

Viral
The group M subtypes included in the WHO HIV-1 RNA Genotype Reference Panel (subtypes A, B, C, D, AE, F, G, and AG-GH) were diluted to 400 copies/mL in pooled HIV-negative plasma samples, on the basis of the quantification data provided by NIBSC. Groups N and O were extracted neat, because no accurate quantification was supplied for these samples. The WHO reference panel and clinical samples (240 mL) were subjected to extraction with the use of a QIAamp Viral RNA kit (Qiagen) and were eluted in a volume of 120 mL. Further evaluation of the SAMBA HIV-1 test chemistry was performed using surplus nucleic acid extracts for nucleotide sequencing from clinical samples provided blindly and anonymized by The Royal London Hospital (London); nucleic acid extraction was performed in accordance with the sample preparation module of the ViroSeq HIV-1 Genotyping system (version 2.0; Abbott Laboratories).
Nucleic acid amplification and detection. Amplification of the target nucleic acid sequence of HIV-1 in the SAMBA format is achieved by an isothermal amplification method [16] , which is completed in 60 min. The amplified viral nucleic acid is further detected by the proprietary method for dipstick-based detection of nucleic acid, as described elsewhere [14, 17] .
A TaqMan technology-based real-time quantitative polymerase chain reaction (PCR) assay used for evaluation of the detection step of the SAMBA test was performed with a Brilliant Two-Step Quantitative RT-PCR Core Reagent kit and an Mx4000 Multiplex Quantitative PCR system (Stratagene), as described elsewhere [15] .
USER SURVEY IN RESOURCE-LIMITED SETTINGS
Resource-limited health care settings in developing countries encompass a wide range of capabilities with different levels of equipment, facilities, and training of personnel. To establish the test specifications suitable for most such settings, we conducted a survey of potential end users at 32 sites involved in the care of ∼18,000 patients with HIV infection or AIDS in the following countries: Burma, China, Cô te D'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Kenya, Honduras, Malawi, Mozambique, Nigeria, South Africa, Tanzania, Thailand, Uganda, Ukraine, and Zambia. Respondents selected the site description as local or district hospital (19 sites), clinic (10 sites), reference laboratory (2 sites), or research center (1 site). Most of the sites surveyed (including clinics) either are run by international nongovernmental organizations or have an international collaborator or sponsor, in the absence of which the delivery and monitoring of ART would not be possible. These sites thus have access to resources and tests that would not normally be available in such deprived settings. As a result of these external sources of support, the clinics are as well resourced in terms of access to specialist staff and testing methods as are many of the hospitals included in the survey. The survey compiled information on site infrastructure, resources, and current approaches to the monitoring and treatment of patients with HIV infection or AIDS (Table 1) . Infrastructure considered essential in laboratories of the developed world was lacking, with only 83% and 77% of sites having access to a stable electricity supply and a source of deionized water, respectively. Such basic laboratory equipment as bench-top centrifuges and heating blocks were available at 80% and 57% of sites, respectively, with 72% of sites possessing pipettors capable of dispensing !1 mL, which is essential for an accurate viral load quantification assay. The lack of deionized water and micropipettors at some sites suggested the necessity of providing predispensed buffers and reagents loaded in test kit disposables. Air conditioning was available at approximately half of the sites, prohibiting the widespread use of tests requiring a controlled temperature environment. Biosafety cabinets were available in fewer than half of the sites, revealing a lack of ability to comply with safety standards and to prevent environmental contamination with amplicons as well as pointing to a requirement for the amplification and detection steps of the test to be performed in a closed system. The lack of refrigerators at 10% of sites also suggests that the test should be capable of functioning over a wide range of ambient temperatures based on reagents that do not require cold storage. Given these conditions, it was not surprising that 62% of sites did not have access to viral load tests, with only 3 of these sites being able to request such a test at an off-site facility, requiring cold-chain transportation of the sample and delays of several weeks in obtaining the test result. At many sites, only non-laboratory-trained personnel are available to perform testing. Prices of currently available tests ($25-$130) are well above the affordable level. Respondents desired tests with a simple and rapid format, such as visual detection by dipstick, that can be performed while patients are at the Second-generation detection has an optimized labeling format, resulting in a detection limit of !500 copies/mL, compared with a limit of 5000-10,000 copies/mL for the first generation.
clinic, allowing a rapid response to patient needs in an environment blighted by delays in patient contact and follow-up. In summary, the results of the survey suggested that for a test to be useful in such settings, it must be simple, robust, inexpensive, stable, and self-contained, with predispensed unit-dose reagents and disposables included and with a design and procedure that comply with biosafety standards.
SAMBA HIV-1 NAT PLATFORM
The simple and rapid SAMBA HIV-1 test for visual detection of the viral genome in a closed system was designed primarily to assist health care workers in developing countries with the early diagnosis of HIV-1 infection and with monitoring of ART. The test procedure comprises 3 basic steps: (1) sample preparation for extraction of viral RNA, (2) isothermal amplification of the viral nucleic acid, and (3) rapid visual detection of the amplification products with a dipstick. Because access to separate and dedicated laboratory spaces for sample preparation, amplification, and detection is not feasible in resource-limited settings, the most technically challenging steps of the SAMBA HIV-1 test, amplification and detection, are combined and performed in a sealed disposable cartridge that allows containment of the amplified product. The sealed SAMBA cartridge contains all of the required reagents and components necessary for nucleic acid amplification and dipstick detection ( Figure 1A ), thereby preventing carry-over contamination of amplicons. After the extracted nucleic acid sample is introduced, the cartridge design allows for the mixing of different reagents and incubation with the processed sample in a defined sequential manner. The operation of the cartridge is automated with the use of a simple and easy-to-use POC machine ( Figure 1B ) that was designed around the disposable cartridge device. Processing of steps 2 and 3 by the POC machine lasts ∼1.5 h. The integrated SAMBA system design allows the user to load the device, push a button, and walk away until the amplification and detection steps are complete ( Figure 1C) . The semi-automated assay procedure thus requires minimal user intervention. The POC machine currently processes 1 sample at a time but will be adapted to process batches of 5-10 samples simultaneously.
A synthetic nontarget nucleic acid has been incorporated into the SAMBA HIV-1 test as an internal control to verify the reliability of the assay procedure and to indicate any carry-over of inhibitors from the sample. The internal control was designed so that it would not affect the sensitivity of HIV-1 detection. It is added with the plasma sample during sample preparation, coamplified with the HIV-1 target, and detected at a second capture line on the dipstick embedded in the SAMBA device ( Figure 1A ). The SAMBA test is designed to be robust under field conditions and stable in high humidity and temperature. The test components, including 4 buffers, 5 lyophilized reagent spheres, and a dipstick, are all formulated to be stable at room temperatures of up to 37ЊC and, thus, do not require cold-chain transportation and refrigeration. Each of the components was tested in accelerated stability experiments for at least 1 month at 55ЊC and found to be stable. Long-term stability tests at room temperature or 37ЊC of the most perishable assay components (amplification enzymes) revealed that their activity was undiminished after storage for at least 12 months. All the necessary components are preloaded into disposables, circumventing the need for accurate pipetting and for nuclease-free handling. Different dyes are added during lyophilization to each of the assay reagent spheres to allow their differentiation and, thus, facilitate the manufacturing and packing process.
The SAMBA HIV-1 test can be performed within 2 h, from sample collection to result, allowing the clinician to make informed clinical management decisions while the patient is onsite. This approach offers a clear advantage over current methods that require the sample to be sent to a centralized laboratory for testing.
Sample preparation. The lack of simple and inexpensive sample extraction methods capable of recovery or liberation of nucleic acid targets with high efficiency is a key bottleneck for application of currently available NATs in resource-limited settings [7] . Currently available commercial methods for extraction of HIV-1 RNA rely on chaotropic salts, such as guanidinium thiocynate or guanidinium hydrochloride, to denature proteins and inhibit nucleases during RNA extraction (Table  2 ) [18] . Other common extraction methods use organic solvents, such as phenol-chloroform and isoamyl alcohol, to remove proteins by phase separation [19, 20] . Chaotropic salts, phenol, and chloroform are hazardous and toxic, resulting in adverse effects if released into the environment. In the industrialized world, these chemicals are handled in a laboratory with safety equipment, such as a fume hood, and are disposed of through professional waste-disposal services. In addition, currently available commercial extraction kits use ethanol to wash and purify the extracted nucleic acid, which is often carried over into the sample extracts, resulting in inhibition of the subsequent amplification process. Consequently, most commercial methods for extraction of HIV-1 nucleic acid are thus not appropriate for use in resource-limited settings. Sample preparation for the SAMBA HIV-1 test is an aqueous-based extraction method specifically designed for performance in such a setting. The SAMBA reagents are nontoxic, and the method can be performed without elaborate safety measures. The procedure relies on an aqueous wash buffer, which is compatible with and does not inhibit the downstream amplification step.
Unlike most commercial extraction kits, which require storage of reagents at 4Њ or Ϫ20ЊC, SAMBA extraction reagents do not require cold storage (Table 2) , rendering them suitable for use in the field. In addition, the SAMBA buffers are available in unit doses and do not require additional preparation. In contrast, most commercial extraction kits require end users separately to add carrier RNA or ethanol (Table 2 ). These additional steps are prone to human error and, thus, may result in failure or loss of accuracy of the diagnostic test. The SAMBA sample preparation step is currently being automated and will be integrated with the amplification and detection device to allow sample-in-results-out testing with minimal user intervention.
Amplification and detection. SAMBA relies on a dipstickbased system for rapid visual detection of amplified viral nucleic acid within 25 min [14] . This instrument-independent approach is the core of the SAMBA test and greatly reduces cost and complexity, compared with conventional NATs, by obviating the requirement for expensive equipment to detect a fluorescence or chemiluminescence signal. Dipstick-based assays have not traditionally been used for the detection of nucleic acids because of the inherent insensitivity of the format. This limitation has been overcome in the SAMBA platform by the use of a signal amplification system that improves the sensitivity of detection of DNA or RNA targets and by techniques that increase the amount of target captured on the solid phase of the dipstick (Figure 2A ) [17, 21] . Optimization of the signal amplification system labeling format resulted in a 500-1000-fold increase in assay sensitivity for the optimized second-generation detection, compared with the first-generation detection ( Figure 2B ). Such improvement is especially important for samples that contain endogenous inhibitors of the amplification enzymes.
The optimized chemistry of the visual detection system incorporated into the SAMBA platform is capable of simultaneous identification and discrimination of amplified nucleic acid sequences from 3 viral targets (HIV-1 and hepatitis B and C viruses) in a single sample [14] . The dipstick detection system was validated by blind testing of 295 clinical plasma specimens, consisting mostly of those obtained from the blood bank in Kumasi, Ghana. The performance of dipstick detection was evaluated by comparison with detection on the basis of a fluorescent TaqMan probe and a quantitative PCR system costing ∼$50,000. The dipstick-based detection shows high sensitivity and specificity that are equal to, if not better than, those of complex, instrument-dependent TaqMan PCR for the detection of a wide range of viral loads in clinical samples [14] . The usefulness and potential of the dipstick detection system for settings with limited resources and overstretched health care budgets have been seen by operators of blood services in Saudi Arabia [10] .
The isothermal amplification of the HIV-1 genome in SAMBA format negates the need for an expensive thermocycler. The ∼60-min amplification time is faster than that required for traditional PCR thermal cycling. The primer and probe sequences are targeted to conserved regions of the HIV-1 genome to maximize amplification and detection of all known subtypes of HIV-1.
Performance. The SAMBA platform was designed primarily for use in developing countries, where HIV-1 non-B subtypes and circulating recombinant forms (CRFs) are prevalent. The amplification and detection chemistry of the test was first assessed, independently of the cartridge and POC machine, with the WHO HIV-1 RNA Genotype Reference Panel (NIBSC code 01/466), WHO Second International Standard, together with clinical samples containing CRFs, such as CRF02_AG, that are common in Africa. All of the HIV-1 subtypes of group M were detected at a level of 400 copies/mL, as were strains of groups N and O ( Figure 3A) . The clinical samples containing CRF02_AG were also detected by the test (Figure 3A and 3B) .
The SAMBA amplification and detection chemistry were tested with the specimens provided by The Royal London Hospital. These samples encompassed 14 different viral subtypes or CRFs with viral loads of 78-copies/mL, as deter- (Table 3) .
The sensitivity and reproducibility of the SAMBA HIV-1 test were evaluated with a serially diluted in-house panel prepared from cultured HIV-1 subtype B, which was quantified with the use of the Roche COBAS Amplicor Test. Six operators performed a total of 24 tests for each sample, with the results showing that the detection limit of the assay is ∼200 copies/ mL for a plasma input volume of 240 mL. The sensitivity and subtype coverage of the SAMBA HIV-1 test are thus at least as good as those of commercially available HIV-1 diagnostic tests performed with a similar sample input volume (Table 4) .
CONCLUSIONS
Because of the ever-expanding epidemic of HIV-1 infection, there is an urgent need for high-quality and affordable HIV-1 diagnostic tests in developing countries, where currently available tests are neither affordable nor accessible. These tests are also not optimized for the HIV-1 subtypes and CRFs present in the developing world. However, the clinical samples from an inner London hospital tested in the present study exemplify the wide variety of HIV-1 subtypes and CRFs now found in the developed world. The problems associated with detection of HIV-1 subtypes and recombinants are thus no longer restricted to developing countries. The diagnostic needs of developed countries are now changing as a result of markedly increasing health care costs and the move toward a decentralized testing environment. The development of high-quality, simplified, and more affordable assays, such as SAMBA, would also fill this gap created by the increasing decentralization of testing in settings with few resources in developed countries.
The SAMBA HIV-1 test has a substantial advantage over currently available NATs, in that it is able to provide results quickly and on-site, thereby facilitating appropriate clinical support. The simplicity of SAMBA tests will allow their use in resource-poor settings in developing countries and for nearpatient testing in the developed world. The SAMBA platform is not restricted to HIV-1 diagnostics but rather can be adapted for use in the diagnosis of other infections and has the capability of multiplex testing [14] . The generic SAMBA system should prove to be readily adaptable to detection of different infectious agents and could be rapidly modified for detection of newly emerging viral and bacterial strains.
